500 related articles for article (PubMed ID: 29061540)
1. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC
J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
[TBL] [Abstract][Full Text] [Related]
5. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
[TBL] [Abstract][Full Text] [Related]
7. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
8. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
9. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.
Ankerst DP; Miyamoto R; Nair PV; Pollock BH; Thompson IM; Parekh DJ
J Urol; 2009 May; 181(5):2071-5; discussion 2076. PubMed ID: 19286205
[TBL] [Abstract][Full Text] [Related]
10. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH
Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
Pereira-Azevedo N; Braga I; Verbeek JF; Osório L; Cavadas V; Fraga A; Carrasquinho E; Cardoso de Oliveira E; Nieboer D; Roobol MJ
Int J Urol; 2017 Dec; 24(12):826-832. PubMed ID: 28901582
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
13. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Kundu SD; Grubb RL; Roehl KA; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1116-20. PubMed ID: 15758718
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
[TBL] [Abstract][Full Text] [Related]
15. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen as a predictor of an abnormal digital rectal examination.
Lui PD; Terris MK; Haney DJ; Constantinou CE; Stamey TA
Br J Urol; 1994 Sep; 74(3):337-40. PubMed ID: 7524998
[TBL] [Abstract][Full Text] [Related]
17. Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review.
Pepe P; Panella P; D'Arrigo L; Savoca F; Pennisi M; Aragona F
Oncology; 2006; 70(2):81-9. PubMed ID: 16601365
[TBL] [Abstract][Full Text] [Related]
18. Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.
Vickers A; Vertosick EA; Sjoberg DD; Roobol MJ; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2017 Mar; 197(3 Pt 1):607-613. PubMed ID: 27693450
[TBL] [Abstract][Full Text] [Related]
19. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
20. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
